It has been a very good year for Seattle Genetics (NASDAQ:SGEN) and its investors. Sales of Adcetris posted solid results in its first full year on the market, and high-profile collaborations with AbbVie (NYSE:ABBV) and Bayer (NASDAQOTH:BAYRY) helped the company's sales climb to $269 million in 2013, up from $211 million in 2012.
Seattle Genetics hopes an international roll-out of Adcetris by its co-developer, Takeda, along with data from ongoing late stage studies, will provide the catalysts necessary for a repeat performance in 2014.
Building a franchise
Adcetris is not only Seattle Genetics' first commercial drug; it's also a great marketing tool for the company's unique antibody drug conjugate technology. The drug, approved to treat relapsing Hodgkin's lymphoma, or HL, and as a second-line treatment for anaplastic large-cell lymphoma, or ALCL, cleared or elicited a response in 73% of HL patients receiving it during trials.
Seattle Genetics stands to receive even more money from Takeda this year. Overseas sales of Adcetris are eclipsing $100 million, resulting in a $5 million milestone payment that Seattle Genetics will recognize this quarter. Importantly, Seattle Genetics' royalty payment climbs from the teens on sales under $100 million, to a mid-twenties rate on sales above $100 million. Seattle Genetics will also receive another $9 million milestone from Takeda once pricing is negotiated for the drug's use in Japan.
That rising overseas revenue stream is great news for Seattle Genetics, but a much larger sales opportunity exists if Adcetris' label expands to include more indications. Adcetris is currently used only in HL patients relapsing after both stem cell transplant and two prior chemotherapies. Winning approval as a first line, or as a pre-chemo treatment, would significantly expand Adcetris patient pool given more than 9,000 cases of HL are diagnosed annually, according to the National Cancer Institute.
We'll gain insight into whether Adcetris can address that larger population when results from Seattle Genetics' Aethera phase 3 trial are un-blinded ahead of schedule later this year. In this trial, Adcetris is being evaluated as a pre-chemotherapy option for HL patients who didn't respond to a stem cell transplant. If data are favorable, Seattle Genetics hopes to file for approval in early 2015. Another phase 3 trial is judging whether Adcetris can replace Bleomycin in the most common chemotherapy cocktail used in HL patients.
Outside of HL, Seattle Genetics believes there's an opportunity for Adcetris as a front-line treatment for large B-cell lymphoma, or DLBCL, for which the company received FDA orphan designation last year. Seattle Genetics is also evaluating Adcetris as a frontline drug for mature T-cell lymphoma, or MTCL, and relapsed cutaneous T-cell lymphoma, or CTCL.
Partnering for success
Adcetris potential is compelling, but may end up dwarfed by collaborations Seattle Genetics has inked with big pharmaceutical companies, including AbbVie and Bayer.
In AbbVie's case, the company has expanded its relationship with Seattle Genetics twice since the two first linked up in 2011. AbbVie handed over another $25 million up front and promised as much as $255 million in milestone payments per research target in January. If AbbVie can successfully combine Seattle Genetics' ADC technology with its cancer compounds, it will pay Seattle Genetics mid- to high-single-digit percentage royalty on any future sales.
AbbVie's deal is similar to the one cut with Bayer last summer. In that deal, Bayer agreed to pay Seattle Genetics $20 million up front and as much as $500 million in milestone payments if compounds combining Bayer's oncology drugs with Seattle Genetics' technology advance through clinic. Bayer also agreed to future royalties if any drugs covered by the deal are ever commercialized.
Fool-worthy final thoughts
Overall, Seattle Genetics and Takeda have more than 30 trials under way for Adcetris, including four that are in phase 3. This suggests a significant opportunity exists to expand Adcetris revenue. How big an opportunity remains an area for debate, but during Seattle Genetics' third quarter earnings conference call, the company speculated peak Adcetris sales could someday reach $1 billion a year in the U.S. alone. That suggests investors should focus on Adcetris trial data this year to gauge whether Seattle Genetics' lofty peak sales projections may prove fact or fiction.
Even Seattle Genetics may have trouble keeping up with this stock in 2014
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Seattle Genetics. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.